Last reviewed · How we verify

Sulfur Colloid

University of California, San Diego · FDA-approved active Small molecule Quality 35/100

Technetium Tc 99m Sulfur Colloid is used for imaging by entering lymphatic capillaries, mixing with peritoneal fluid, or being taken up by the reticuloendothelial system.

Technetium Tc 99m Sulfur Colloid, marketed by the University of California, San Diego, is a radiopharmaceutical used primarily for lymph node localization in breast cancer or melanoma. Its key strength lies in its mechanism of action, which allows it to effectively enter lymphatic capillaries and be taken up by the reticuloendothelial system, enhancing diagnostic accuracy. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition and potential revenue erosion.

At a glance

Generic nameSulfur Colloid
Also known as99mTc-SC, 99mTc-SC Sulfur Colloid
SponsorUniversity of California, San Diego
ModalitySmall molecule
PhaseFDA-approved

Mechanism of action

When injected subcutaneously, Technetium Tc 99m Sulfur Colloid travels through lymphatic capillaries to lymph nodes, aiding in the detection of nodal metastasis. When injected intraperitoneally, it mixes with peritoneal fluid, and its clearance rate helps assess shunt patency. Intravenous injection allows imaging of reticuloendothelial system-rich structures.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results